Etude : PREPARE /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme / Nom
Situation thérapeutique
Traitement
Cadre réglementaire
MÀJ
Présentation de l'étude
Acronyme / Nom : PREPARE

Situation thérapeutique :

Traitement :

Cadre réglementaire : RIPH3

Dernière MÀJ : 22/10/2021
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Place de l'intervention gériatrique chez les sujets âgés traités pour un cancer

Spécialité : Toutes tumeurs solides
Localisation : C - Toutes localisations
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : Randomized trials have already demonstrated that geriatric intervention was able to improve survival in the general elderly population but only a few have been performed in cancer patients. At the end, these data are not sufficient to consider geriatric intervention as validated in this setting. Case Management, coordinated by a geriatrician and a trained nurse, could improve prognosis of elderly patients with cancer. This approach, can be integrated in daily oncology practice. This strategy will be compared to usual oncological management in a randomized phase III trial.

Patients will first be screened using the G8 screening tool. If the resulting score is altered (G8 <= 14), patients will be included in the main study and randomized according to 2 modalities: Arm A / Usual care (treatment according to on-going regimens in oncology) or Arm B /Case management (assessment of the patient by the nurse and the geriatrician with interventions as prescribed by the geriatrician). The intervention will be considered effective if, at one year, compared to usual care there is a significant clinical improvement in overall survival (OS) without a significant deterioration or/and clinical improvement of at least one of the targeted quality of life (QoL) scores, without significant clinical deterioration in at least one of the targeted QoL scores and without significant difference in OS in favor of usual care.

If the resulting score is normal (G8 > 14), patients will be treated according to their physician-in-charge opinion. A minimal set of data will be collected (age, sex, tumor type, disease stage, performance status (PS), creatinine clearance, albumin and C-Reactive Protein (CRP) levels mainly) to allow for the characterization of the population in order to compare our results to those of other published series.

Phase : III

Stade : Localisé à Métastatique

NA
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : - Patient older 70 years and older
- Performance status 0 to 3 (WHO)
- G8 and QLQ-C30 questionnaires 'score are available
- No previous geriatric evaluation during cancer treatment
- Locally advanced or metastatic disease :
-> 1st line medical treatment :
--> Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
--> Colon and rectum : metastatic (unresectable metastasis),
--> Prostate cancer : metastatic and refractory to hormonal castration,
--> Bladder cancer : locally advanced or metastatic,
--> Ovarian cancer : advanced stage (IIb to IV),
--> Lung cancer : metastatic non-small cell,
--> Lymphomas (indolent and aggressive)
-> Or 2nd line medical treatment :
--> Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative,
--> Colon and rectum : metastatic (unresectable metastasis),
--> Prostate cancer : metastatic and refractory to hormonal castration,
--> Ovarian cancer : advanced stage (IIb to IV),
--> Lymphomas (indolent and aggressive)
- Life expectancy over 6 months
- Signed informed consent
- Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).

Critères de non-inclusion : - Patient who already received 2 medical treatment lines
- Exclusive 1st or 2nd treatment lines of :
-> Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed),
-> Surgery,
-> Radiotherapy,
- "Best supportive care" treatment
- Patient unable to understand quality of life questionnaire
- Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons.
- Patient placed under guardianship
- Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE
- Previous enrolment in the present study
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT02704832
Promoteur :
Institut Bergonié
Type de sponsor : Institutionnel
229 Cours de l'Argonne - 229 Cours de l'Argonne
33000 BORDEAUX

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
CHU de Rouen - 1 Rue de Germont - 76000 ROUEN

Investigateur :
Dr Pierre MICHEL

TEC / ARC / IDE :
Non communiqué

Statut de l'essai : À VENIR

MAJ : 22/10/2021